1

1 Cited Publications

Target:

Research Areas:

CPD-10 is a potent CCND1 and CDK4 PROTAC degrader. CPD-10 exhibits anti-proliferative effects on tumor cells and can also induce apoptosis. CPD-10 can be used for the study of breast cancer and lung cancer .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

SGF29-IN-1

1 Cited Publications

Cat. No.: HY-158009

CAS No.: 6638-82-0

Purity: ≥98.0%

Target:

Histone Acetyltransferase

Research Areas:

Cancer

SGF29-IN-1 (Compound Cpd_DC60) is a selective inhibitor for Spt-Ada-Gcn5 acetyltransferase (SAGA)–associated factor 29 (SGF29)-Tudor domain. SGF29-IN-1 exhibits activity against leukemia .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

Anti-Canine PD-L1/B7-H1 Antibody (JC071)

1 Cited Publications

Cat. No.: HY-P990114

Anti-Canine PD-L1/B7-H1 Antibody (JC071) is an anti-canine PD-L1/B7-H1 IgG1 monoclonal antibody. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can specifically bind to CHO-PDL1 cells and K562-cCD20-cPD-L1 cells. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can enhance the level of IFN-γ. Anti-Canine PD-L1/B7-H1 Antibody (JC071) is often used in western blot experiments .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

CPD-1224

Cat. No.: HY-153386

CAS No.: 2891620-68-9

Purity: 99.83%

Target:

Anaplastic lymphoma kinase (ALK)

Research Areas:

Cancer

CPD-1224 is an orally effective ALK inhibitor, a derivative of an ALK inhibitor that connects to the cereblon ligand. CPD-1224 targets the EML4-ALK oncogenic fusion protein and degrades both ALK and the mutant forms L1196M/G1202R. CPD-1224 can slow down tumor growth .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

C188

Cat. No.: HY-112338

CAS No.: 823828-18-8

Purity: 98.29%

Synonyms: Cpd188

Target:

STAT Apoptosis

Research Areas:

Cancer

C188 (CPD188) is a STAT3 inhibitor with anticancer effects. C188 inhibits STAT3 SH2/pY-peptide binding (IC₅₀ of 20 µM against pY-peptide binding) and IL-6-mediated STAT3 phosphorylation. C188 is selective for STAT3 over STAT1. C188 inhibits nuclear-to-cytoplasmic translocation of Stat3. C188 shows highly active induces apoptosis in breast cancer cell lines with constitutive Stat3 activation (EC₅₀s of 0.73 µM, 3.96 µM, and 7.01 µM in MDA-MB-468, MDA-MB-231, and MDA-MB-435 cultures, respectively) .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

CPD-39

Cat. No.: HY-168664

CAS No.: 3055472-38-0

Target:

PROTACs CDK

Research Areas:

Cancer

CPD-39 is a potent and orally active CCND1 and CDK4 heterobifunctional PROTAC degrader. CPD-39 shows anti-proliferation .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

Gilvetmab

Cat. No.: HY-P99641

CAS No.: 1808081-43-7

Gilvetmab is a canine-derived anti-cPD-1 monoclonal antibody, as well as an immune activator/antitumor agent. Gilvetmab binds to canine PD-1, blocks the interaction of PD-1/PD-L1/L2, prevents immunosuppression, reactivates antitumor responses, induces tumor regression or disease stabilization, and may also trigger pseudoprogression. Gilvetmab can be used in research related to malignant melanoma and mast cell tumors .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

tert-Butyl (7-aminoheptyl)carbamate

Cat. No.: HY-22391

CAS No.: 99733-18-3

Synonyms: tert-Butyl 2,8-diaminooctanoate

Target:

PROTAC Linkers

Research Areas:

Cancer

tert-Butyl (7-aminoheptyl) carbamate (tert-Butyl 2,8-diaminooctanoate) is a PROTAC linker that can be used in research related to PROTAC synthesis. tert-Butyl (7-aminoheptyl) carbamate serves as the linker for CPD-10 (HY-168660) .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

BR-cpd7

Cat. No.: HY-163705

Target:

PROTACs FGFR

Research Areas:

Cancer

BR-cpd7 is an orally active, selective PROTAC degrader targeting FGFR1 and FGFR2, with a DC₅₀ of 2.2 nM against FGFR1. BR-cpd7 reduces FGFR signaling. BR-cpd7 induces cell cycle arrest and selectively blocks the proliferation of FGFR1/FGFR2-dependent tumor cells. BR-cpd7 exhibits significant antitumor efficacy in FGFR1-dependent lung cancer animal models, while achieving complete depletion of FGFR1. BR-cpd7 can be used for cancer-related research .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

Smurf1-IN-5

Cat. No.: HY-174416

CAS No.: 1824647-09-7

Target:

E1/E2/E3 Enzyme

Research Areas:

Cardiovascular Disease

Smurf1-IN-5 (Compound cpd-6) is an allosteric SMAD ubiquitin regulatory factor 1 (SMURF1) inhibitor. Smurf1-IN-5 leads to a reduction in the ubiquitylation of substrates such as BMPR2 (bone morphogenetic protein receptor 2) and SMAD1, enhancing the BMP (bone morphogenetic protein) signaling pathway. Smurf1-IN-5 is promising for research of pulmonary arterial hypertension (PAH) .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

ERCC1-XPF-IN-1

Cat. No.: HY-143498

CAS No.: 2411584-25-1

Target:

DNA/RNA Synthesis

Research Areas:

Cancer

ERCC1-XPF-IN-1 is a potent and high-affinity ERCC1-XPF inhibitor with IC₅₀ value of 0.49 μM. ERCC1-XPF-IN-1 has the capacity to potentiate the cytotoxicity effect of UV radiation and inhibiting DAN repair, by the inhibition of removal of CPDs, and cyclophosphamide toxicity to colorectal cancer cells .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

CU-CPD107

Cat. No.: HY-147310

CAS No.: 2573912-32-8

Purity: 98.07%

Target:

Toll-like Receptor (TLR)

Research Areas:

Infection

CU-CPD107 is a potent, selective toll-like receptor 8 (TLR 8) agonist. CU-CPD107 inhibits TLR8 signaling. CU-CPD107 converts to synergistic agonist activities in the presence of ssRNA and induces TLR8 signaling. CU-CPD107 inhibits proinflammatory factor expression and avoids immune responses in the presence of ssRNA .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

CPD-2828

Cat. No.: HY-174991

Target:

IRE1

Research Areas:

Neurological Disease Cancer

CPD-2828 is an orally active and selective IRE1α inhibitor with an IC₅₀ value of 1.2 μM. CPD-2828 is promising for research of endoplasmic reticulum stress-related diseases (e.g., cancer, neurodegenerative diseases) .

Compare

loading...